Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
GW Pharmaceuticals
GW Pharmaceuticals
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
The British biopharmaceutical company has released Q4 and 2019 financial year results
Regulatory
GW Pharmaceuticals gains product recognition by NHS England
Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence
Manufacturing
Momentum in the US cannabidiol market gains retailers' attention
Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory
First prescription CBD from GW Pharma has restriction lowered
The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Regulatory
First plant-derived cannabinoid prescription gains FDA approval
GW Pharmaceuticals has announced FDA approval of EPIDIOLEX (cannabidiol) oral solution, a medication prescribed for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome
GW Pharmaceuticals receives orphan drug designation for cannabidiol
The European Medicines Agency granted the designation based on findings from the physician-led cannabidiol expanded access programme
Research & Development
GW Pharmaceuticals announces appointments to Board of Directors
Subscribe now